BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2019 and reiterated its full-year 2019 total product revenue guidance.

"2019 has been a year of significant progress for Vertex across all parts of our business. With the historic approval of TRIKAFTA, we are now one step closer to providing treatment for up to 90% of all people with CF. We've also had tremendous success bringing our CF medicines to more patients globally with reimbursement agreements recently reached in England, Spain, Australia, and Scotland, and through label expansions to younger patients," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "The company also continues to successfully execute on our strategy of creating transformative medicines for serious diseases through serial innovation. The rapid progress of our pipeline is expected to yield proof-of-concept data in multiple diseases in 2020, which will position Vertex for continued growth in the years ahead."

Third-Quarter 2019 Financial Highlights

Three Months Ended September 30,

%

2019

2018

Change

(in millions, except per share amounts)

Total product revenues, net

$

950

$

783

21%

KALYDECO

$

249

$

246

ORKAMBI

$

297

$

282

SYMDEKO/SYMKEVI

$

404

$

255

GAAP Operating income

$

99

$

206

(52)%

Non-GAAP Operating income

$

403

$

295

37%

See the original post here:
Vertex Reports Third-Quarter 2019 Financial Results - Business Wire